CDP 571

Drugs in R and D

Volumn 4, Issue 3, 2003, Pages 174-178

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BAY 103356; BAY W 3356; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; UNITED KINGDOM;

EID: 0038447041     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304030-00006     Document Type: Article

References (15)

1. Dhainaut J-FA, Vincent J-L, Richard C. et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Critical Care Medicine 23: 1461-1469, Sep 1995
2. Celltech Group plc. Celltech Announces Results From CDP 571 Phase III Studies in Crohn's Disease. Media Release : 30 Jul 2002. Available from: URL: http://www.celltechgroup.com
3. Hamauer S, Present D, Sandborn W. et al. CDP571, a novel humanized anti-TNF-alpha antibody: a well tolerated option for Crohn's disease after previous hypersensitivity to infliximab. American J Gastroenterology 97 (Suppl.): 277, Sep 2002
4. Ofei O, Hurel S, Newkirk J. et al. Effects of an engineered human TNF-alpha antibody (CDP571) on insulin sensitivity and glycaemic control in patients with non-insulin-dependent diabetes mellitus. Diabetic Medicine 12 (Suppl. 2): 15, 1995
5. Warren BF, Watkins PE, Foulkes R. Anti TNF alpha treatment of a model of human ulcerative colitis. Gut 35 (Suppl. 2): 50, 1994
6. Bloxham DP. Therapeutic applications of anti-TNF monoclonal antibodies. Expert opinion on Investigational Drugs 3: 907-912, Sep 1994
7. Watkins PE, Foulkes R, Stephens S. The treatment of ulcerative colitis with anti-tumour necrosis factor alpha antibody. Falk Symposium Inflammatory Bowel Diseases : 178, 29 Jun 1995
8. Rankin ECC, Ravirajan CT, Ehrenstein MR. et al. Serological effects following treatment with an engineered human anti-TNF alpha antibody, CDP571, in patients with rheumatoid arthritis. British Journal of Rheumatology 34 (Suppl. 1): 101, 1995
9. Choy EHS, Kassimos D, Kingsley GH. et al. The effect of an engineered human anti-tumour necrosis factor alpha antibody on interleukin-6 and bone markers in rheumatoid arthritis patients. Arthritis and Rheumatism 38 (Suppl.): 185, Sep 1995
10. Stack WA, Mann SD, Roy AJ. et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349: 521-524, 22 Feb 1997
11. Feagan BG, Sandborn WJ, Baker JP. et al. A randomized, double-blind, placebo-controlled, multicenter trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gut 45 (Suppl. V): 131, Nov 1999
12. Sandborn WJ, Targan SR, Wolf DC. et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for the induction and maintenance of clinical improvement in patients with moderate to severely active Crohn's disease. Gut 45 (Suppl. V): 133, Nov 1999
13. Feagan BG, Sandborn WJ, Baker JP. et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 118 (Suppl. 2): 655, Part 1, Apr 2000
14. Sandborn WJ, Feagan BG, Hanauer SB. et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330-1338, May 2001
15. Rankin ECC, Choy EHS, Kassimos D. et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatology 34: 334-342, Apr 1995